Balaji Venugopal

6.2k total citations · 2 hit papers
56 papers, 1.4k citations indexed

About

Balaji Venugopal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Balaji Venugopal has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 17 papers in Surgery. Recurrent topics in Balaji Venugopal's work include Renal cell carcinoma treatment (27 papers), Renal and related cancers (12 papers) and Economic and Financial Impacts of Cancer (10 papers). Balaji Venugopal is often cited by papers focused on Renal cell carcinoma treatment (27 papers), Renal and related cancers (12 papers) and Economic and Financial Impacts of Cancer (10 papers). Balaji Venugopal collaborates with scholars based in United Kingdom, United States and France. Balaji Venugopal's co-authors include Nial Wheate, Jane A. Plumb, David Stirling, Paola Nativo, David J. Flint, P. R. Edwards, Sarah D. Brown, J.L. Smith, Duncan Graham and Natarajan Sathiyamoorthy Venkataramanan and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Balaji Venugopal

46 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin

2010 678 citations Balaji Venugopal, Jane A. Plumb et al. profile →
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

2023 114 citations Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Balaji Venugopal

Since Specialization

Citations

This map shows the geographic impact of Balaji Venugopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Balaji Venugopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Balaji Venugopal more than expected).

Fields of papers citing papers by Balaji Venugopal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Balaji Venugopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Balaji Venugopal. The network helps show where Balaji Venugopal may publish in the future.

Co-authorship network of co-authors of Balaji Venugopal

This figure shows the co-authorship network connecting the top 25 collaborators of Balaji Venugopal. A scholar is included among the top collaborators of Balaji Venugopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Balaji Venugopal. Balaji Venugopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study. 2025 ·Journal of Clinical Oncology ·Guillermo de Velasco, Laurence Albigès, Thomas Powles, Cristina Suárez, (unknown), Mauricio Burotto, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, (unknown), Rodolfo F. Perini, Donna Vickery, Brian I. Rini, Toni K. Choueiri	0
2	The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis 2024 ·SHILAP Revista de lepidopterología ·(unknown), Michael Sullivan, (unknown), Nicole De La Mata, Angela C Webster, Balaji Venugopal, Robert J. Jones, Ninian N. Lang, Patrick B. Mark, Jennifer S. Lees	0
3	Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients 2024 ·Clinical Science ·(unknown), (unknown), (unknown), (unknown), Alasdair Henderson, J. Andrew McClure, (unknown), Balaji Venugopal, Pam McKay, Piotr J. Slomka, (unknown), (unknown), (unknown), Ninian N. Lang	0
4	Clinical Practice Recommendations for Antithrombotic Management of Peripheral Artery Disease: An Indian Perspective 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), R. George, (unknown), Prem Chand Gupta, (unknown), Balaji Venugopal, Rajiv Parakh, (unknown), (unknown), (unknown), Ravul Jindal	0
5	Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials 2024 ·JACC CardioOncology ·(unknown), (unknown), Robert J. Jones, Balaji Venugopal, Patrick B. Mark, Jennifer S. Lees, Mark C. Petrie, Ninian N. Lang	1
6	Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study. 2023 ·Journal of Clinical Oncology ·Paul Nathan, Jennifer Allison, Natalie Charnley, Richard W. Griffiths, Agnieszka Michael, (unknown), Anand Sharma, Bernadett Szabados, Balaji Venugopal, (unknown), Valérie Perrot, Áine M. Prendergast, (unknown), James Larkin	2
7	Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC). 2023 ·Journal of Clinical Oncology ·(unknown), Mark Stares, Robert J. Jones, Stefan N. Symeonides, (unknown), (unknown), (unknown), Sarah Slater, (unknown), Jahangeer Malik, (unknown), (unknown), Balaji Venugopal	1
8	Resilience of hospital and allied infrastructure during pandemic and post pandemic periods for maternal health care of pregnant women and infants in Tamil Nadu, India ‐ A counterfactual analysis 2023 ·PLoS ONE ·(unknown), (unknown), Sarthak Gupta, (unknown), (unknown), Balaji Venugopal	0
9	Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study 2023 ·Clinical Genitourinary Cancer ·(unknown), (unknown), A. Meerveld-Eggink, Francesca Jackson‐Spence, Kathrine S Rallis, Paul Brian, (unknown), Christopher C.T. Sng, (unknown), (unknown), (unknown), Naomi Anderson, Axel Bex, Thomas Powles, Balaji Venugopal, Bernadett Szabados	2
10	Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer breakdown → 2023 ·New England Journal of Medicine ·Stephen J. Freedland, Murilo Luz, Ugo De Giorgi, Martin Gleave, Geoffrey Gotto, Christopher Pieczonka, Gabriel P. Haas, Choung‐Soo Kim, M. Backhaus, Antti Rannikko, Jamal Tarazi, Swetha Sridharan, Jennifer Sugg, Yiyun Tang, Ronald Tutrone, Balaji Venugopal, Arnauld Villers, Henry H. Woo, Fabian Zohren, Neal D. Shore	114
11	Influence of tumor size in the progression of venous tumor thrombus in renal cell carcinoma 2022 ·Urology Annals ·(unknown), Jai Prakash, (unknown), (unknown), (unknown), Balaji Venugopal, Ananthakrishnan Sivaraman, Nitesh Jain, (unknown), (unknown), (unknown), (unknown), Rajesh Paul, (unknown), R. Balasubramaniam, Narasimhan Ragavan	3
12	Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes 2021 ·Clinical Genitourinary Cancer ·Balaji Venugopal, Manon Pillai, Thomas Powles, Philip Savage, Agnieszka Michael, Kate Fife, (unknown), Valérie Perrot, Bernadett Szabados	6
13	Retrohepatic Caval Leiomyosarcoma Antesitum Resection: A Case Report and a Review of Literature 2021 ·Journal of Clinical and Experimental Hepatology ·(unknown), (unknown), (unknown), Balaji Venugopal, (unknown)	2
14	VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis 2021 ·British Journal of Cancer ·Steve Nicholson, Holly Tovey, Tony Elliott, Stephanie Burnett, Clare Cruickshank, Amit Bahl, Peter Kirkbride, Anita Mitra, Alastair Thomson, Naveen Vasudev, Balaji Venugopal, (unknown), (unknown), Bruno Morgan, (unknown), Emma Hall, Lisa Pickering	8
15	A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma 2018 ·British Journal of Cancer ·Natalie Cook, Bristi Basu, D. M. Smith, Aarthi Gopinathan, Jonathan J. Evans, William P. Steward, Daniel H. Palmer, David Propper, Balaji Venugopal, (unknown), Alan Anthoney, Lisa V. Hampson, Michael Nebozhyn, David A. Tuveson, (unknown), Helen Turner, (unknown), Sarah Halford, Duncan I. Jodrell	96
16	Interesting case of left subclavian pseudoaneurysm in a child managed successfully 2018 ·Indian Journal of Thoracic and Cardiovascular Surgery ·(unknown), (unknown), Balaji Venugopal, (unknown)	0
17	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, (unknown), Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	97
18	Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma 2013 ·BMC Urology ·Balaji Venugopal, Jawaher Ansari, Michael Aitchison, Lye Mun Tho, (unknown), Robert J. Jones	13
19	Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect 2012 ·Metallomics ·Jane A. Plumb, Balaji Venugopal, Rabbab Oun, Natividad Gomez-Roman, Yoshiyuki Kawazoe, Natarajan Sathiyamoorthy Venkataramanan, Nial Wheate	87
20	Conversion from cyclosporin to tacrolimus in a patient with prolonged acute tubular necrosis 1997 ·Transplant International ·Gareth Morris‐Stiff, Adam Jurewicz, Balaji Venugopal, Keshwar Baboolal, Richard H. Moore, Peter Griffin, Rozanne Lord	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact